Asia Pacific Biosimilar Contract Manufacturing Market Size & Outlook
The biosimilar contract manufacturing market in Asia Pacific is expected to reach a projected revenue of US$ 7,572.0 million by 2033. A compound annual growth rate of 14.5% is expected of Asia Pacific biosimilar contract manufacturing market from 2025 to 2033.
Revenue, 2024 (US$M)
$2,242.1
Forecast, 2033 (US$M)
$7,572.0
CAGR, 2025 - 2033
14.5%
Report Coverage
Asia Pacific
Global Market
Related Markets
Asia Pacific biosimilar contract manufacturing market highlights
- The Asia Pacific biosimilar contract manufacturing market generated a revenue of USD 2,242.1 million in 2024.
- The market is expected to grow at a CAGR of 14.5% from 2025 to 2033.
- In terms of segment, recombinant non-glycosylated proteins was the largest revenue generating type in 2024.
- Recombinant Glycosylated Proteins is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, Japan is expected to register the highest CAGR from 2025 to 2033.
Asia Pacific data book summary
| Market revenue in 2024 | USD 2,242.1 million |
| Market revenue in 2033 | USD 7,572.0 million |
| Growth rate | 14.5% (CAGR from 2025 to 2033) |
| Largest segment | Recombinant non-glycosylated proteins |
| Fastest growing segment | Recombinant Glycosylated Proteins |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, IQVIA Holdings Inc, AGC Biologics, Samsung BioLogics, WuXi Biologics (Cayman) Inc, Rentschler Biopharma SE, Avid Bioservices Inc, FUJIFILM Holdings Corp, Thermo Fisher Scientific Inc, Biocon, Boehringer Ingelheim, Element Materials Technology, Alcami |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 28.6% of the global biosimilar contract manufacturing market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 7,572.0 million by 2033.
No credit card required*
Publish Date: Aug 26, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Biosimilar Contract Manufacturing Market Scope
Biosimilar Contract Manufacturing Market segmentation & scope
Rheumatoid Arthritis
Biosimilar Contract Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| FUJIFILM Holdings Corp | View profile | 83,784 | 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 | www.fujifilmholdings.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | www.boehringer-ingelheim.com/ |
| WuXi Biologics (Cayman) Inc | View profile | 12,740 | No. 108, Meiliang Road, Mashan Binhu District, Wuxi, China, People's Republic of, 214092 | www.wuxibiologics.com |
| Catalent Inc | View profile | 17,219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | www.catalent.com |
| IQVIA Holdings Inc | View profile | 87,000 | 2400 Ellis Road, Durham, NC, United States, 27703 | www.iqvia.com |
| Rentschler Biopharma SE | View profile | 501-1000 | Laupheim, Baden-Wurttemberg, Germany, Europe | www.rentschler-biopharma.com |
| AGC Biologics | View profile | 1001-5000 | Bothell, Washington, United States, North America | www.agcbio.com/ |
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.samsungbiologics.com/ |
Asia Pacific Biosimilar Contract Manufacturing Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Biosimilar Contract Manufacturing Market Outlook will help companies and investors design strategic landscapes.
Recombinant Non-Glycosylated Proteins was the largest segment with a revenue share of 62.87% in 2024.
Horizon Databook has segmented the Asia Pacific biosimilar contract manufacturing market based on recombinant non-glycosylated proteins, recombinant glycosylated proteins covering the revenue growth of each sub-segment from 2021 to 2033.
- Asia Pacific Biosimilar Contract Manufacturing Market Product Outlook (Revenue, USD Million , 2021-2033)
- Recombinant Non-Glycosylated Proteins
- Recombinant Glycosylated Proteins
- Asia Pacific Biosimilar Contract Manufacturing Market Production technology Outlook (Revenue, USD Million , 2021-2033)
- Mammalian
- Non-Mammalian
- Asia Pacific Biosimilar Contract Manufacturing Market Application Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- Blood Disorders
- Growth Hormonal Deficiency
- Rheumatoid Arthritis
- Chronic and Autoimmune Disorders
- Others
Reasons to subscribe to Biosimilar Contract Manufacturing Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Biosimilar Contract Manufacturing Market Outlook databook
- Our clientele includes a mix of Biosimilar Contract Manufacturing Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific Biosimilar Contract Manufacturing Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific Biosimilar Contract Manufacturing Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Asia Pacific Biosimilar Contract Manufacturing Market, 2021-2033 (US$M)
Asia Pacific Type - Biosimilar Contract Manufacturing Market Statistics, 2024 - 2033 (US$M)
